Navigation

🏠 Home 📰 Latest News 🌍 World 🇮🇳 India 💼 Business 💻 Technology ⚽ Sports 🎬 Entertainment 🏥 Health
Biggest News Aggregation in the World
📰 About Iga News

About Iga News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from About Iga. Real-time updates on events, politics, business and more.

Novartis iptacopan meets primary endpoint in new rare kidney disease trial

November 24, 2023
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)Ad hoc announcement pursuant to Art. 53 LRPhase III APPLAUSE-IgAN study met its pre-specified interim analysis primary endpoint, demo...
United States Shreeram Aradhye Novartis Pharmaceuticals European Medicines Agency Exchange Commission Novartis Biomedical Research
Source: pharmiweb.com

Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023

April 1, 2023
SAN DIEGO, April 01, 2023 -- Travere Therapeutics, Inc. today announced publication in The Lancet of the interim analysis of efficacy and safety data from the ongoing pivotal, Phase 3 PROTECT... | April 1, 2023
Krung Thep Mahanakhon United States Naomi Eichenbaum Nivi Nehra Brad Rovin Division For Nephrology
Source: marketscreener.com

Travere Therapeutics, Inc.: Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023

April 1, 2023
SAN DIEGO, April 01, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced publication in The Lancet of the interim analysis of efficacy and safety data from the ongoing pivotal
United States Krung Thep Mahanakhon Nivi Nehra Naomi Eichenbaum Brad Rovin European Union
Source: finanznachrichten.de

Ligand's Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy

February 18, 2023
First single molecule Dual Endothelin Angiotensin Receptor Antagonist (DEARA) approved for use in patients with IgA nephropathy (IgAN)Interim results from the ongoing Phase 3 PROTECT head-to-head trial demonstrated a rapid, sustained and clinically meaningful reduction in proteinuria vs. active control, irbesartanLi...
Deric Dube Simon Latimer Bruce Voss Todd Davis Gilead Sciences Ligand Pharmaceuticals
Source: pharmiweb.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Sparsentan for the Treatment of IgA Nephropathy

May 16, 2022
PDUFA target action date of November 17, 2022SAN DIEGO, May 16, 2022 -- Travere Therapeutics, Inc. today announced the U.S. Food and Drug Administration has accepted and granted Priority Review... | May 16, 2022
United States Deric Dube Chris Cline Exchange Commission Drug Administration Europe Union
Source: marketscreener.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science